Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201172
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tagliamento, Marco | - |
dc.contributor.author | Gennari, Alessandra | - |
dc.contributor.author | Lambertini, Matteo | - |
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Harbeck, Nadia | - |
dc.contributor.author | Mastro, Lucia del | - |
dc.contributor.author | Aguilar Company, Juan | - |
dc.contributor.author | Bower, Mark | - |
dc.contributor.author | Sharkey, Rachel | - |
dc.contributor.author | Pria, Alessia dalla | - |
dc.contributor.author | Plaja, Andrea | - |
dc.contributor.author | Jackson, Amanda | - |
dc.contributor.author | Handford, Jasmine | - |
dc.contributor.author | Sita-Lumsden, Ailsa | - |
dc.contributor.author | Martínez Vila, Clara | - |
dc.contributor.author | Matas, Marta | - |
dc.contributor.author | Miguel Rodríguez, Ana | - |
dc.contributor.author | Vincenzi, Bruno | - |
dc.contributor.author | Tonini, Giuseppe | - |
dc.contributor.author | Bertuzzi, Alexia | - |
dc.contributor.author | Brunet, Joan | - |
dc.contributor.author | Pedrazzoli, Paolo | - |
dc.contributor.author | Avanzo, Francesca d' | - |
dc.contributor.author | Biello, Federica | - |
dc.contributor.author | Sinclair, Alasdair | - |
dc.contributor.author | Lee, Alvin J.X. | - |
dc.contributor.author | Rossi, Sabrina | - |
dc.contributor.author | Rizzo, Gianpiero | - |
dc.contributor.author | Mirallas, Oriol | - |
dc.contributor.author | Pimentel, Isabel | - |
dc.contributor.author | Iglesias, María | - |
dc.contributor.author | Sanchez de Torre, Ana | - |
dc.contributor.author | Guida, Annalisa | - |
dc.contributor.author | Berardi, Rossana | - |
dc.contributor.author | Zambelli, Alberto | - |
dc.contributor.author | Tondini, Carlo | - |
dc.contributor.author | Filetti, Marco | - |
dc.contributor.author | Mazzoni, Francesca | - |
dc.contributor.author | Mukherjee, Uma | - |
dc.contributor.author | Diamantis, Nikolaos | - |
dc.contributor.author | Parisi, Alessandro | - |
dc.contributor.author | Aujayeb, Avinash | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Libertini, Michela | - |
dc.contributor.author | Grisanti, Salvatore | - |
dc.contributor.author | Rossi, Maura | - |
dc.contributor.author | Zoratto, Federica | - |
dc.contributor.author | Generali, Daniele | - |
dc.contributor.author | Saura, Cristina | - |
dc.contributor.author | Lyman, Gary H. | - |
dc.contributor.author | Kuderer, Nicole M. | - |
dc.contributor.author | Pinato, David J. | - |
dc.contributor.author | Cortellini, Alessio | - |
dc.date.accessioned | 2023-07-25T11:24:32Z | - |
dc.date.available | 2023-07-31T05:10:31Z | - |
dc.date.issued | 2023-01-31 | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201172 | - |
dc.description.abstract | PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. RESULTS By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented >= 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19-specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls. CONCLUSION Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19. | ca |
dc.format.extent | 17 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | American Society of Clinical Oncology (ASCO) | ca |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1200/JCO.22.01667 | - |
dc.relation.ispartof | Journal of Clinical Oncology, 2023, vol. 41, num. 15, p. 2800-2814 | - |
dc.relation.uri | https://doi.org/10.1200/JCO.22.01667 | - |
dc.rights | (c) American Society of Clinical Oncology et al, 2023 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Breast cancer | - |
dc.title | Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-13T08:52:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36720089 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jco.22.01667.pdf | 420.12 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.